Physician profile
John Jackson
NPI 1487689840
$355.49
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.62 · 2021: $283 · 2022: $57.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.77 | 2021-2022 | |
| Ibsa Pharma INC. | $40.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.47 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $28.22 | 2021 | |
| Eisai INC. | $21.94 | 2021 | |
| Glaxosmithkline, LLC. | $19.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.27 | 2021 | |
| Zyla Life Sciences, INC. | $14.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.